Literature DB >> 15194177

Diagnosis and differential assessment of pulmonary arterial hypertension.

Robyn J Barst1, Michael McGoon, Adam Torbicki, Olivier Sitbon, Michael J Krowka, Horst Olschewski, Sean Gaine.   

Abstract

Pulmonary arterial hypertension (PAH) is diagnosed by various investigations that are essential for making the diagnosis, and by additional tests to clarify the category of pulmonary hypertension (PH). A diagnostic algorithm can guide the evaluation of PH, but like all guidelines the algorithm can be modified according to specific clinical circumstances. Most patients are diagnosed as the result of an evaluation of symptoms, whereas others are diagnosed during screening of asymptomatic populations at risk. Right heart catheterization (RHC) must be performed in patients with suspected PH to establish the diagnosis and document pulmonary hemodynamics. Before initiation of medical therapy, assessment of acute vasoreactivity (during catheterization) is necessary to determine the appropriate therapy for an individual patient. An acute response is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or below, accompanied by a normal or high cardiac output. After PAH is diagnosed, disease severity should be assessed in order to accurately determine risk:benefit profiles for various therapeutic options. Useful tools to predict outcome include functional class, exercise capacity, pulmonary hemodynamics, acute vasoreactivity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and troponin levels. Repeating these tests serially on treatment is useful for monitoring the response to a given therapy. Close follow-up at a center specializing in management of PH is recommended, with careful periodic reassessment and adjustment of therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15194177     DOI: 10.1016/j.jacc.2004.02.032

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  202 in total

1.  Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing.

Authors:  Douglas L Prisco; Anthony L Sica; Arunabh Talwar; Mangala Narasimhan; Kennedy Omonuwa; Babak Hakimisefat; Sophy Dedopoulos; Nawid Shakir; Harly Greenberg
Journal:  Sleep Breath       Date:  2010-10-07       Impact factor: 2.816

2.  Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

Authors:  Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

3.  C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure.

Authors:  Funda Aksu; Nermin Capan; Kurtuluş Aksu; Ruhsar Ofluoğlu; Sema Canbakan; Bünyamin Yavuz; Kadir Okhan Akin
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

4.  Time-resolved magnetic resonance angiography: evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension.

Authors:  Hyun J Jeong; Parmede Vakil; John J Sheehan; Sanjiv J Shah; Michael Cuttica; James C Carr; Timothy J Carroll; Amir Davarpanah
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

5.  Oxidative stress in patients with COPD and pulmonary hypertension.

Authors:  Pavol Joppa; Darina Petrásová; Branislav Stancák; Zuzana Dorková; Ruzena Tkácová
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

6.  Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.

Authors:  Hiroshi Fujita; Yoshihiro Fukumoto; Kenya Saji; Koichiro Sugimura; Jun Demachi; Jun Nawata; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

7.  Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension.

Authors:  Sebastian Ley; Derliz Mereles; Michael Puderbach; Ekkehard Gruenig; Helena Schöck; Monika Eichinger; Julia Ley-Zaporozhan; Christian Fink; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2007-01-16       Impact factor: 5.315

8.  Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension.

Authors:  Andreas Zierer; Rochus K Voeller; Spencer J Melby; Paul Steendijk; Marc R Moon
Journal:  Eur J Anaesthesiol       Date:  2009-03       Impact factor: 4.330

Review 9.  Right ventricular failure complicating heart failure: pathophysiology, significance, and management strategies.

Authors:  Mobusher Mahmud; Hunter C Champion
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

10.  Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.